Searching “What is Prostamax” usually brings up two very different things: a prostate supplement and a research peptide. This guide focuses on the peptide version—Prostamax (often called KEDP)—and explains what it is, what the evidence really shows, and how to avoid buying the wrong molecule. If you’re familiar with GLP‑1 (glucagon-like peptide-1) weight‑loss peptides, the mechanisms here are completely different. [1]
Fast Answer / Executive Summary
Prostamax is a short synthetic “bioregulator” peptide most commonly described as the tetrapeptide Lys‑Glu‑Asp‑Pro (KEDP) studied in prostate and immune‑cell models. It is not an FDA‑approved drug, and most evidence is preclinical (animals/cell culture). Use the name carefully—some sellers label different sequences as “Prostamax.” [2]
Key takeaway: Most “Prostamax” peptide content online refers to KEDP (Lys‑Glu‑Asp‑Pro), but product labeling is not standardized—verify the sequence and documentation before trusting the name. [3]
Core Concepts & Key Entities
What is Prostamax in the peptide context?
Prostamax (peptide) is most often defined as KEDP—an ultra‑short tetrapeptide with the amino acid sequence Lys‑Glu‑Asp‑Pro. [4]
You’ll also see it written as H‑Lys‑Glu‑Asp‑Pro‑OH (the same peptide with chemistry notation that shows the N‑ and C‑termini), or described by its “letter code” KEDP (K = lysine, E = glutamic acid, D = aspartic acid, P = proline). [5]
In the “Khavinson peptide” ecosystem, Prostamax/KEDP is usually discussed as a tissue‑associated peptide bioregulator with research interest in prostate models and immune/aging biology (especially chromatin structure). [6]
Why the name “Prostamax” is easy to misunderstand
“Prostamax” is not a single, universally standardized product name. That’s the first thing beginners trip over.
There are at least two common uses of the word:
- Dietary supplement products using herbal ingredients such as saw palmetto (Serenoa repens), nettle, or pygeum—marketed for “prostate support.” [7]
- Research peptide listings that often describe Prostamax as KEDP (Lys‑Glu‑Asp‑Pro), sold in lyophilized vials and typically labeled “research use only.” [8]
Information gain (important reality check): Even within peptide sellers, some pages labeled “Prostamax” list different sequences. For example, one vendor page lists Prostamax as a 16‑amino‑acid sequence (Tyr‑Leu‑Arg‑Ile‑Val‑Gln‑Cys‑Arg‑Ser‑Val‑Glu‑Gly‑Ser‑Cys‑Gly‑Phe), which is not the KEDP tetrapeptide. [9]
That mismatch is not a small detail. If the sequence differs, you are looking at a different molecule, and you should assume differences in: – mechanism,
– dosing math,
– safety profile,
– and relevance of any cited studies. [10]
What does “bioregulator peptide” mean?
A “bioregulator” (in this context) refers to short peptides proposed to influence gene expression and cell behavior, often framed as tissue‑specific regulators. This is distinct from the way most mainstream therapeutic peptides are described in Western drug development (e.g., receptor agonists like GLP‑1 receptor agonists). [11]
The bioregulator concept is frequently tied to the work of Vladimir Khavinson[12] and collaborators, who have published on short peptides and their potential roles in aging biology and epigenetic regulation. [13]
How is Prostamax (KEDP) thought to work?
Prostamax (KEDP) is mainly discussed as an epigenetic/chromatin‑related modulator in research models. [14]
Here’s the plain‑English translation of what those papers and protocols mean:
- Chromatin is the “packaging” of DNA inside the nucleus. When chromatin is tightly packed (heterochromatin), many genes are less accessible for transcription. [15]
- In a study in older human subjects, short peptides including Prostamax were associated with changes consistent with chromatin decondensation (loosening) in lymphocytes. [16]
- A separate review in Stem Cell Reviews and Reports describes short peptides as capable (in the authors’ framing) of penetrating cells and participating in epigenetic regulation of gene expression, including genes involved in differentiation. [17]
Simple analogy (useful for beginners): If DNA is a cookbook, chromatin packing determines whether pages are clipped shut or easy to open. The proposed “bioregulator” mechanism is that short peptides may help “unclip” some pages—changing which recipes the cell can read. [18]
What evidence exists for prostate-related outcomes?
The strongest publicly accessible evidence for prostate outcomes under the “Prostamax/KEDP” label is preclinical (rat models) and not a substitute for human clinical trials. [19]
Two commonly cited experimental papers in a journal called Modern Research in Inflammation report findings in rats:
- In a chronic aseptic prostatitis model, ProstaMax/Prostamax administration was reported to reduce histologic signs of inflammation and reduce fibrotic/sclerotic changes. [20]
- In a benign prostatic hyperplasia (BPH) model, a tetrapeptide (Lys‑Glu‑Asp‑Pro) was reported to reduce prostate weight/volume and affect epithelial measures compared with a Serenoa repens comparator in that model. [21]
A separate patent describing lysyl‑glutamyl‑aspartyl‑proline (Lys‑Glu‑Asp‑Pro) claims prostate‑function regulation and includes experimental descriptions and clinical examples; treat this as developmental/patent literature, not the same evidentiary level as peer‑reviewed randomized trials. [22]
Is Prostamax a GLP‑1 peptide?
No—Prostamax (KEDP) is not a GLP‑1 (glucagon-like peptide‑1) receptor agonist and is not in the incretin class. GLP‑1 peptides are typically discussed in the context of glucose regulation, appetite, and weight management, while Prostamax is discussed in the context of chromatin/gene regulation and prostate tissue models. [23]
Regulatory reality and safety framing
Most Prostamax peptide listings you’ll see are labeled “research use only” and explicitly state they are not approved medicines and not for human or animal consumption. [24]
For example, one seller states the products are for research/laboratory use only, not evaluated by the FDA, and that bodily introduction is prohibited. [25]
This article is educational and does not provide medical advice or prescriptions.
Step‑by‑Step / How‑To
If you want to understand Prostamax without getting misled, follow this sequence/verification-first workflow. [26]
- Verify what “Prostamax” means on your specific source page.
- Confirm the sequence (KEDP vs something else).
- Check documentation (COA, identity testing, endotoxin if relevant).
- Only then look at protocols and dosing math for that exact molecule.
- Compare what the evidence supports (animals vs humans) before drawing conclusions. [27]
Step: Confirm which “Prostamax” you’re actually dealing with
You should treat the product name as a marketing label until you confirm the amino acid sequence. [10]
In the peptide bioregulator community, “Prostamax” usually means KEDP (Lys‑Glu‑Asp‑Pro). But at least one vendor listing labeled Prostamax provides a different (16‑amino‑acid) sequence, which would make it a different peptide entirely. [9]
Practical rule: If the sequence is not Lys‑Glu‑Asp‑Pro (or the molecular formula/MW match the KEDP tetrapeptide), do not assume that KEDP research applies. [3]
Step: Anchor your understanding to primary identifiers
A reliable Prostamax (KEDP) identity profile usually includes all of the following: – Sequence: Lys‑Glu‑Asp‑Pro (KEDP) [28]
– Molecular formula and size consistent with a tetrapeptide (the patent describes C_{20}H_{33}N_{5}O_{9} and ~487.5 molecular weight for Lys‑Glu‑Asp‑Pro without counterion). [22]
– Clear “research use only” labeling and documentation that matches the sequence. [29]
This matters because peptide names can be reused across: – capsule supplements,
– tinctures,
– and totally different peptide sequences. [30]
Step: Read the evidence in the right order
Start with the most direct model evidence, then move outward. [31]
A clean way to do that:
- Mechanism layer: short peptide + chromatin/gene regulation literature (helps you understand the “bioregulator” claim). [32]
- Organ model layer: prostatitis and BPH animal models where Lys‑Glu‑Asp‑Pro was directly tested. [33]
- Human relevance layer: recognize that animal histology changes do not automatically imply clinical benefit for human LUTS, BPH, or prostatitis symptoms—especially without randomized trials. [34]
Step: Understand a typical educational protocol (and what it is not)
Most online Prostamax “dosage protocols” are educational extrapolations from preclinical work and are not medical instructions. [35]
On PeptideDosages.com, the Prostamax educational protocol describes: – a once‑daily intramuscular approach,
– a gradual titration from 0.5 mg to 1 mg daily,
– and a practical dilution of 20 mg reconstituted with 2.0 mL to reach 10 mg/mL. [36]
It also notes a critical limitation plainly: human clinical trial data are not published and dosing is extrapolated from animal models. [37]
Step: If you handle injectables in any context, use real‑world safety standards
If a person is considering any injection practice, sterility, dose accuracy, and evidence-based injection technique standards are non-optional—and a licensed clinician is the correct authority. [38]
General intramuscular standards for adults (in the context of vaccination) from U.S. Centers for Disease Control and Prevention[39] describe typical needle gauges and lengths and emphasize appropriate site selection. [40]
On the question of aspiration (pulling back on the plunger before injecting), multiple sources note that routine aspiration is no longer recommended in vaccine IM administration guidance. [41]
To be clear: these references address vaccination technique; they do not “approve” non‑medical injection of research peptides, and they do not replace medical supervision.
Comparison / Alternatives
Prostamax (KEDP) is best viewed as an experimental research peptide, while BPH and prostatitis symptoms have established clinical evaluation pathways and guideline‑supported treatments. [42]
Prostamax (KEDP) vs common prostate-support options
The table below compares what people usually mean when they ask “Prostamax vs X,” using an evidence lens (human guideline evidence vs preclinical). [43]
| Option | Primary “target” | Evidence strength (humans) | Typical role | Key tradeoff |
| Prostamax (KEDP) | Proposed chromatin/gene regulation in tissue models | Limited/unclear (mostly preclinical; some patents/limited publications) | Research context; mechanistic exploration | High uncertainty translating animal histology to symptom relief in humans [44] |
| Alpha‑blockers (e.g., tamsulosin class) | Smooth muscle relaxation → symptom relief | Strong (guidelines/clinical use) | First‑line symptom management for LUTS/BPH in appropriate patients | Can cause side effects; does not directly “shrink” prostate size [45] |
| 5‑alpha‑reductase inhibitors (5‑ARIs) | Hormonal pathway (DHT) → prostate size reduction over time | Strong (guidelines/clinical use) | Often used when prostate enlargement is demonstrable; sometimes combined with alpha‑blockers | Slower onset; potential sexual side effects; medical supervision required [46] |
| Saw palmetto (Serenoa repens) | Mixed proposed mechanisms (anti‑inflammatory/anti‑androgenic in theory) | Mixed; recent high‑quality reviews show little to no benefit alone | OTC supplement used by many; evidence varies by preparation | Quality and efficacy uncertainty; may not outperform placebo in large trials [47] |
| Bioregulatory peptide extracts used clinically in some countries (e.g., Vitaprost class) | Prostate‑targeted peptide extract approaches | Some human clinical literature exists, varying by product and region | Used in certain clinical systems; not the same as KEDP by default | Not interchangeable with KEDP; regulatory status differs by country [48] |
Decisive comparison point: If your goal is evidence-based symptom improvement for LUTS/BPH or clinically diagnosed prostatitis, guideline-supported evaluation and treatments (.e.g., alpha‑blockers/5‑ARIs when appropriate) have far stronger human evidence than Prostamax (KEDP). [42]
What “alternatives” actually mean for different intents
Alternatives depend on intent, and “intent” is what Google is really sorting for. [49]
- If your intent is understanding a peptide bioregulator mechanism, “alternatives” are other short peptides studied in chromatin/aging work (conceptual alternatives, not clinical substitutes). [32]
- If your intent is urinary symptoms or pelvic pain, “alternatives” are clinical evaluation and evidence-based treatments because BPH and prostatitis have multiple causes and categories that guide treatment choice. [50]
- If your intent is supplement shopping, alternatives are other supplement stacks—but the evidence quality is often lower and product variability higher (saw palmetto is a classic example where evidence conclusions have shifted with better trials and newer reviews). [51]
Templates / Checklist / Example
Use this checklist to keep your Prostamax research (and your purchases) grounded in reality instead of hype. [26]
Prostamax verification and use checklist
- Define which “Prostamax” you mean (supplement vs peptide; KEDP vs another sequence). [52]
- Confirm the amino acid sequence on the product page and on the documentation (COA/MS/HPLC). [53]
- Match any research claims you read to the same molecule (don’t apply KEDP data to a 16‑aa peptide or to a saw palmetto supplement). [54]
- Check whether the evidence cited is animal, cell culture, patent, or human trial—and weight your confidence accordingly. [55]
- Calculate concentration and units carefully when reconstituting lyophilized vials (mg ↔ mcg ↔ mL), and document the math. [36]
- Store lyophilized material cold/dry/dark and follow stability guidance after reconstitution (avoid repeated freeze–thaw cycles). [56]
- Track outcomes you can measure (even in self-education): symptoms, sleep, urinary frequency, pain scores—then stop if adverse effects appear. [57]
- Prioritize medical evaluation if symptoms are persistent, severe, or worsening—BPH and prostatitis-like symptoms can overlap with other conditions needing diagnosis. [58]
- Avoid assuming “natural” (supplements) equals “safe” or “research” equals “validated”—both categories can be uncertain in different ways. [59]
- Reassess after a set window and compare against evidence-based options; don’t let sunk-cost bias pick your strategy. [60]
Worked example: Prostamax (20 mg) dilution math (educational)
If a 20 mg KEDP vial is reconstituted with 2.0 mL, the concentration is 10 mg/mL. [36]
From there: – 1 mg = 0.1 mL at 10 mg/mL. [61]
– On a U‑100 insulin syringe, 0.01 mL = 1 unit, so 0.1 mL = 10 units. [61]
That’s why the PeptideDosages educational guide maps: – 0.5 mg → 0.05 mL → 5 units
– 0.75 mg → 0.075 mL → 7.5 units
– 1.0 mg → 0.10 mL → 10 units [36]
Again, this is educational math tied to that specific protocol and does not constitute medical advice.
FAQs
What is Prostamax?
What is Prostamax? Prostamax is most commonly described (in peptide bioregulator contexts) as the tetrapeptide Lys‑Glu‑Asp‑Pro, also called KEDP. It has been studied mainly in preclinical models involving prostate inflammation/hyperplasia and in studies discussing chromatin/gene regulation. Product naming is inconsistent, so confirm the sequence before trusting the label. [2]
Is Prostamax the same as a “Prostamax” prostate supplement?
Is Prostamax the same as a “Prostamax” prostate supplement? No—many “Prostamax” supplements are herbal formulas (often including saw palmetto and other botanicals), while Prostamax in peptide circles usually refers to a synthetic peptide (often KEDP). They are different products with different evidence bases and cannot be compared as if they were interchangeable. [62]
What does KEDP mean?
What does KEDP mean? KEDP is shorthand for the amino acids in the tetrapeptide sequence Lys‑Glu‑Asp‑Pro. In one key naming convention, each amino acid is represented by a single letter: K (lysine), E (glutamic acid), D (aspartic acid), P (proline). When Prostamax is used to mean KEDP, that letter code is the identity anchor. [28]
Is there human clinical trial evidence for Prostamax (KEDP)?
Is there human clinical trial evidence for Prostamax (KEDP)? Publicly accessible, high-quality randomized human trial evidence is limited, and much of what’s commonly cited is preclinical (rats/cell culture) or patent/development literature. Even when animal models show histologic improvements, that does not confirm symptom relief in humans without controlled trials. [63]
How do I make sure I’m buying the “real” Prostamax (KEDP) peptide?
How do I make sure I’m buying the “real” Prostamax (KEDP) peptide? The most reliable approach is to confirm the amino acid sequence and supporting documentation (COA/identity testing), not just the name “Prostamax.” This matters because at least one vendor listing named “Prostamax” provides a non‑KEDP sequence, indicating inconsistent naming across sellers. [9]
Next Steps
If you came here asking “What is Prostamax,” your best next step is to lock down identity first, then decide whether you’re researching a peptide mechanism or looking for symptom-focused clinical solutions. [64]
For a practical, measurement‑friendly educational protocol (including reconstitution math and an example titration schedule), start with the internal guide on PeptideDosages.com[65]: Prostamax 20 mg vial dosage protocol. [66]
If you’re sourcing for laboratory research, this is the external purchase page you provided: Buy Prostamax 20mg from Pure Lab Peptides[67]. Before purchasing, compare the listed sequence and documentation to the KEDP identity profile so you know which molecule you are actually buying. [68]
Main takeaway to remember: Prostamax is usually discussed as the KEDP tetrapeptide (Lys‑Glu‑Asp‑Pro) in preclinical prostate and chromatin research—but name-only shopping is the fastest way to end up with the wrong peptide and the wrong conclusions. [69]
[1] [2] [4] [8] [19] [34] [35] [36] [37] [38] [39] [56] [61] [63] [65] [66] Prostamax Dosage Protocol | PeptideDosages.com
https://peptidedosages.com/single-peptide-dosages/prostamax-20-mg-vial-dosage-protocol/
[3] [22] [28] RU2177802C1 – Tetrapeptide regulating prostate function, pharmacological agent based on thereof and method of its using – Google Patents
https://patents.google.com/patent/RU2177802C1/en
[5] [6] [53] Buy Prostamax (Peptide Bioregulator) (20mg) – 99% Purity USA-Made
https://biolongevitylabs.com/product/prostamax-20mg/
[7] [30] [52] [62] Prostamax – Born Nutrition
https://gobornnutrition.com/prostamax/?utm_source=chatgpt.com
[9] [10] [24] [25] [26] [27] [54] [64] [68] [69] Buy Prostamax 20mg | Research Peptide for Prostate Health
https://purelabpeptides.com/buy-peptides/buy-prostamax-20mg/
[11] [13] [14] [17] [23] [32] Peptide Regulation of Cell Differentiation
https://pubmed.ncbi.nlm.nih.gov/31808038/?utm_source=chatgpt.com
[12] [47] [51] Serenoa repens for benign prostatic hyperplasia
[15] Epigenetic Regulation of Stem Cell Differentiation
https://www.nature.com/articles/pr2006122?utm_source=chatgpt.com
[16] [18] Effects of short peptides on lymphocyte chromatin in senile …
https://pubmed.ncbi.nlm.nih.gov/15085253/?utm_source=chatgpt.com
[20] [31] [33] [43] [44] [55] Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications
https://doi.org/10.4236/mri.2013.23007
[21] Experimental Study of Efficiency of Tertapeptide Lysil-Glutamyl-Aspartyl- Proline Using the Model of Benign Prostatic Hyperplasia
https://doi.org/10.4236/mri.2014.33013
[29] Prostamax – Pure Health Peptides
https://purehealthpeptides.com/product/prostamax/
[40] Vaccine Administration
[41] Chapter 6: Vaccine Administration | Pink Book
[42] [60] management of lower urinary tract symptoms attributed to …
[45] [46] [49] [58] Enlarged Prostate (Benign Prostatic Hyperplasia) – NIDDK
[48] [The use of bioregulatory peptides in the treatment of men …
https://pubmed.ncbi.nlm.nih.gov/34251104/?utm_source=chatgpt.com
[50] [57] [67] Inflammation of the Prostate – NIDDK
[59] Saw Palmetto: Usefulness and Safety – nccih
https://www.nccih.nih.gov/health/saw-palmetto?utm_source=chatgpt.com